Proposed protocol for utilising high-flow nasal oxygen therapy in treatment of dogs hospitalised due to pneumonia

BMC Veterinary Research

Study Protocol

Heli K. Hyytiäinen¹  Anna-Maija Teppo¹  Minna M. Rajamäki¹  Heini Rossi¹ 

[1] Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland;

关键词: Dog;    High-flow nasal cannula;    Hypoxemia;    Non-invasive ventilation;    Optiflow;    Oxygen supplementation;    Respiratory distress;   

DOI  :  10.1186/s12917-023-03737-7

 received in 2023-05-05, accepted in 2023-09-14,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundHigh-flow nasal oxygen (HFNO) therapy is a non-invasive respiratory support method that provides oxygen-enriched, warmed, and humidified air to respiratory-compromised patients. It is widely used in human medical care, but in veterinary medicine it is still a relatively new method. No practical guidelines exist for its use in canine pneumonia patients, although they could potentially benefit from HFNO therapy. This study aims to provide a new, safe, non-invasive, and effective treatment protocol for oxygen supplementation of non-sedated dogs with pneumonia.MethodsTwenty privately owned dogs with pneumonia will receive HFNO therapy at a flow rate of 1–2 L/kg, and the fraction of inspired oxygen will be determined individually (ranging from 21% to 100%). HFNO therapy will continue as long as oxygen support is needed based on clinical evaluation. Patients will be assessed thrice daily during their hospitalisation, with measured primary outcomes including partial pressure of oxygen, oxygen saturation, respiratory rate and type, days in hospital, and survival to discharge.DiscussionThe proposed protocol aims to provide a practical guideline for applying HFNO to dogs hospitalised due to pneumonia. The protocol could enable more efficient and well-tolerated oxygenation than traditional methods, thus hastening recovery and improving survival of pneumonia patients.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

13690_2023_1170_Article_IEq115.gif

12888_2023_5172_Article_IEq24.gif